TPO and autoimmune thrombocytopenic purpura: There are reports overseas that investigated the cost-effectiveness of TPO-RA with standard ITP treatments, including rituximab [9-11], but there are no reports that investigated the cost-effectiveness of splenectomy followed by romiplostim (sequence 1) and splenectomy-romiplostim plus rituximab (sequences 2–3).